TOP1 and systemic sclerosis: The pathogenic effect of SSc-specific autoantibody-containing immune complexes, including anti-DNA topoisomerase I (Scl-70) autoantibody, on endothelial cells has been described, suggesting that these immune complexes trigger activation of the endothelium and disrupt the normal function of TLRs [20].